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concerning intragenic and/or extragenic SNPs. Maternal cell contamination is also
evaluated.
Results: Since 1998 a total of 52 at-risk couples have been supported by the Centro
di Riferimento Regionale Toscano per la Diagnosi Genetica di Fibrosi Cistica. On
44 out of 52 couples, a prenatal test has been performed. Affected fetus resulted
in 9 pregnancies; 2 resulted in a fetal loss after the prenatal sampling, the other
couples have decided for a fetus termination. 3 out of 8 couples, which have chosen
not to proceed with prenatal diagnosis, had spontaneous abortions; 4 out of 8 had
not affected or heterozygous children and only one had two affected children from
two different pregnancies.
Conclusions: The aim of the genetic counselling, which is an important step in
the CF diagnostic iter, is to offer at-risk couples the information concerning CF
hereditary pattern and to evaluate the recurrence risk. Considering that the majority
of couples ask a prenatal screening after the birth of an affected child, in order
to program the other pregnancies it is fundamental for laboratories to optimize the
different methods necessary for CF testing.
The success of CF prenatal diagnosis and other congenital diseases depends on the
effectiveness of a multidisciplinary approach as well as on the genetic counselling.
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Introduction: Lung disease and Pseudomonas aeruginosa (P. aeruginosa) airway
colonization represent a major cause of morbidity and mortality in cystic ﬁbrosis
(CF). Human b-defensin (hBD)-1 is believed to play an important role in mucosal
innate immunity in the lung.
Objective: This study aimed to investigate whether single nucleotide polymor-
phisms (SNPs) of the DEFB1 gene, coding for hBD-1, were associated with
P. aeruginosa airway colonization in CF.
Methods: A total of 182 CF patients bearing the severe/severe CFTR genotype
(carriers of classes I, II, III of CFTR gene mutations) were studied. The SNPs
G-52A, C-44G and G-20A in the 5’-untranslated region of the DEFB1 gene were
genotyped by use of polymerase chain reaction and restriction fragment length
polymorphism. Patients’ sputum samples were collected and analyzed by standard
methods.
Results: We found that carriers of the GA and AA genotypes at the −52 locus site
of the DEFB1 gene had an increased risk of P. aeruginosa chronic colonization than
carriers of the GG genotype (OR adjusted for age 3.21, 95% CI 1.12−9.23, p = 0.03).
Carrying the −44CC and the −20GG genotypes was not related to an increased risk
of colonization with P. aeruginosa as compared to carriers of the −44CG/GG and
the −20GA/AA genotypes, respectively, in this population (ORs adjusted for age
1.37, 95% CI 0.26−7.22 and 0.43, 95% CI 0.13−1.42, respectively; p=ns). Moreover,
in this group of CF patients the ACG haplotype was also signiﬁcantly associated
with P. aeruginosa chronic infection (OR adjusted for age 2.70, 95% CI 1.15−6.36,
p = 0.02).
Conclusion: These results indicate that variant alleles in DEFB1 might contribute
to the colonization of P. aeruginosa in CF.
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We report four cases of anomalous electropherograms obtained after PCR/OLA/SCS
analysis (Abbott), that led to the identiﬁcation of (a) three mutations: two considered
new mutations (E479X, G1247R(G>C)) and another mutation previously described
(I506V); (b) one polymorphism (2752−15C>G) all interfering with this analytical
procedure.
E479X and G1247R mutations were found in two CF subjects who, after
PCR/OLA/SCS, appeared homozygous for F508del and W1282X, although parents’
allelic segregation showed that the F508del and the W1282X mutations were present
in heterozygosity in one parent but absent in the other. Cycle sequencing (Applera)
of exons 10 (E479X) and 20 (G1247R) showed that these subjects were compound
heterozygotes F508del/E479X and W1282X/G1247R(G>C).
E479X mutation originates by nucleotidic change G>T at 1567 in exon 10 with
consequent Glu to Stop change at 479. This CF patient was diagnosed at 1 year
of age by symptoms; he is PI, with sweat chloride at 106mmol/l and moderate
pulmonary disease.
The aminoacidic substitution G1247R has already been described as a disease-
causing CFTR mutation originated by nucleotidic substitution 3871G>A; in this
case, instead, it originates from a 3871G>C nucleotidic substitution, with conse-
quent Glu to Arg change at 1247. This is a causing disease mutation and was found
in a CF patient diagnosed by neonatal screening; she is PS with sweat chloride at
78mmol/l and mild pulmonary disease.
The I506V mutation (previously reported as polymorphism 1648AorG) was found
in the mother of a heterozygous newborn carring F508del. This parent appeared
homozygous for F508del mutation while cycle sequencing of exon 10 showed that
she was compound heterozygous F508del/I506V. Also 2752−15C>G polymorphism
was found during parents’ allelic segregation of a heterozygous newborn carring
2789+5G>A. The mother appeared homozygous for 2789+5G>A mutation while
cycle sequencing of exon 14b (and proximal intronic regions) showed that this
subject had 2789+5G>A on an allele and 2752−15C>G on the other one.
Anomalous electrophoretic patterns of PCR/OLA/SCS assay and inconsistent par-
ents’ allelic segregation have to be checked for sequence variations, possibly
interfering with PCR primers or OLA probes; this should radically reduce wrong
genetic characterizations.
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Introduction: The regulation of the CFTR gene expression has been object of
numerous studies, because in a percentage of CF patients the disease is caused by
alteration of the expression. The analysis of CFTR sequences revealed the absence
of TATA box, but the presence of multiple transcriptional sites. In 2001, a tissue-
speciﬁc DNase I hypersensitive site (DHS) in intron 1 (185+10 kb) of the CFTR
gene was identiﬁed that is required for CFTR expression in the intestinal epithelium,
and other intronic sites are target of regulatory factors. Other still unknown targets
of regulatory factors may be present in CFTR introns. Recently, a comparative
analysis (Homo Sapiens, Mouse, Rat, Zebraﬁsh, Fugu) revealed the presence of a
high number of conserved sequences in human genome. Our group identiﬁed the
‘conserved sequence tags’ (CSTs), i.e., genomic sequences that may be the result
of selective evolutionary pressure for conservation due to a possible functional
role (Boccia A, et al. Nucleic Acid Res, 2005). CST sequences show at least 70%
identity between human and mouse over a length of 100bp. Mutations in these
regions could be responsible of genetic diseases. About 100 CSTs were found in
coding and non-coding regions of CFTR.
Aims: To analyse 52 CFTR intronic CSTs in 37 CF patients bearing one or both
undetected mutations after CFTR gene scanning. CF patients with a known genotype
(n: 23), and non-CF subjects (n: 20) were included in the study as controls.
Methods: We performed multiplex PCR followed by direct sequencing of the 52
CSTs on the DNA extracted from the 90 subjects included in the study.
Results: The study demonstrated that 57.6% of the analysed regions did not show
changes, while in 42.3% of the regions were observed 41 gene variants, including
16 novel. Eleven variants (most novel) were speciﬁcally present in CF patients
bearing undetected mutations. Furthermore, we identiﬁed three novel intragenic
microsatellites: one CA repeat in IVS10 and two PolyA in IVS3 and IVS4
respectively, with a high heterozygosity.
Conclusion: CSTs gene variants might represent causative-mutations; to verify this
hypothesis we will undertake both computational analysis (with known regulatory
motif) and in vitro studies with the “ﬁshing for partners” strategies. The three novel
intragenic microsatellites can be used to improve CF linkage diagnosis.
Acknowledgments: Cystic Fibrosis Foundation of Verona, Italy, is gratefully
acknowledged.
P20 MOLECULAR ANALYSIS OF GENES ENCODING CFTR
INTERACTORS OF SLC26 FAMILY IN CF PATIENTS:
PRELIMINARY RESULTS
R. Tomaiuolo1, G. Cardillo1, A. Elce1, C. Bellia2, V. Raia3, G. Castaldo1.
1CEINGE-Advanced Biotechnologies, scarl, Naples; Dept. of Biochemistry and
Medical Biotechnology, University of Naples “Federico II”, Naples, Italy; 2Lab.
of Clinical Biochemistry, Faculty of Medicine, University of Palermo, Italy; 3Dept.
of Pediatrics, University of Naples “Federico II”, Naples, Italy
Introduction: The SLC26 (Solute Linked Carrier) are a gene family encoding
highly versatile anion exchangers, involved in many physiological processes, like
trans epithelial NaCl transport and bicarbonate secretion. Actually, about 10 proteins
belong to this family and some of them are related to human diseases, like
SLC26A3 that is the disease gene of a rare and severe form of chronic chloride
loosing diarrhoea (CLD). Two domains of SLC26A3 protein, the “STAS-like” and
PDZ domains, play a critical role in its activation and bicarbonate secretion. This
